Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530256 · ClinicalTrials.gov registry record · Phase 1
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
A Phase 1 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01530256: Clinical Trial Phase 1 study, sponsored by CSL Behring.
NCT01530256 is a Phase 1 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01530256, a Phase 1 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.
Interventions
- BIOLOGICAL ALD518
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Why NCT01530256 stopped before completion
NCT01530256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which ALD518 is the first listed.
NCT01530256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01530256 about?
NCT01530256 is a clinical study titled "Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)". The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.
What is the current status of trial NCT01530256?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01530256?
The interventions under investigation include: ALD518 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01530256?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01530256's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia